CD8A and breast cancer: This suggests that the immune subtype ICS-A with a lower proportion of CD8 T cells but a higher proportion of M2 macrophages may have an immunosuppressive (immune rejection) phenotype, and M2 macrophages or CD8 T cells may provide a therapeutic target for future breast cancer immunotherapy.